Back to search
FDAFDA · Food and drugs·Recall number D-0251-2026

Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.

Published January 14, 2026 · Recall initiated: December 18, 2025

Summary

FDA records drug Class II recall D-0251-2026, published January 14, 2026 and initiated December 18, 2025. Recalling firm: Imprimis NJOF, LLC; Status: Ongoing; Reported quantity: 314 boxes of 6,280 pre-filled syringes; Lot: Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of particulate matter - Glass like particles.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Imprimis NJOF, LLC
Distributor
U.S Nationwide
Lot
Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06. recalled?

Yes. FDA published recall D-0251-2026 on January 14, 2026. Reported hazard: Presence of particulate matter - Glass like particles.

What should I do if I have this product?

Voluntary: Firm initiated · Letter